Transdermal testosterone in women aged 35-55 years with SSRI- or SNRI-induced female sexual dysfunction
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2013
Price : $35 *
At a glance
- Drugs Testosterone (Primary)
- Indications Female sexual dysfunction
- Focus Therapeutic Use
- 09 Nov 2013 New trial record
- 12 Oct 2013 Primary endpoint 'Sexual-functioning' has not been met.
- 12 Oct 2013 Results presented at the 24th Annual Meeting of the North American Menopause Society.